{"id":"W4364353540","doi":"10.1007/s10637-022-01326-3","title":"Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors","year":2023,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Selumetinib; Nausea; Discontinuation; Vomiting; MEK inhibitor; Internal medicine; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Population; Cancer; Phases of clinical research; Surgery; Oncology; Chemotherapy; MAPK/ERK pathway; Kinase; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000456161,0.0001893296,0.0002719948,0.00006823256,0.00009886398,0.00002360562,0.0005599764,0.00004890947,0.000004735067],"category_scores_gemma":[0.0004671018,0.0001078812,0.0000274494,0.000557275,0.0001904914,0.00002477321,0.0002936637,0.0001167322,0.000003268069],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001853144,"about_ca_system_score_gemma":0.000736823,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000162852,"about_ca_topic_score_gemma":0.0003220102,"domain_scores_codex":[0.9980991,0.0002506662,0.0005900408,0.00038123,0.0004701078,0.000208847],"domain_scores_gemma":[0.9987298,0.00007928668,0.0003911722,0.0004975296,0.000184709,0.0001174715],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01975987,0.0180606,0.009852589,0.000286603,0.0007556628,0.00004744045,0.02467008,0.008747662,0.8830355,0.000764109,0.02108073,0.01293909],"study_design_scores_gemma":[0.1275139,0.01932903,0.05420246,0.0004365739,0.0001782096,0.000008406724,0.007006855,0.001108771,0.7857473,0.00135837,0.002297256,0.0008127438],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978496,0.00001549836,0.00000419744,0.0002855925,0.0001372259,0.001340407,0.0002547932,0.000009410813,0.0001032146],"genre_scores_gemma":[0.997847,0.000002072513,0.0008768906,0.0002105345,0.00008691421,0.00008713097,0.0003978047,0.00002589268,0.0004657223],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1077541,"threshold_uncertainty_score":0.4399268,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0347956569583104,"score_gpt":0.3114770306345717,"score_spread":0.2766813736762613,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}